Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

A Q2 2026 Playbook for Navigating Market Uncertainty

For investors looking to rebalance in Q2, here are three stocks that combine growth and defense to help investors stay invested during volatile markets

MarketBeat

2 Safe Dividend Stocks to Buy and Hold Forever

These are two dividend stocks that you can confidently buy, hold, and forget about for decades.

Barchart

From pilot mania to portfolio discipline: how the best companies are escaping AI purgatory

Most companies have dozens of AI pilots and almost nothing to show for it. The ones breaking through have stopped experimenting and started betting.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

When Fear Hits the Stock Market, Where Can Investors Find Safety?

Our senior market strategist takes a look at traditionally defensive sectors to find opportunities in the current market uncertainty.

Barchart

Is There Such a Thing As a Safe Stock? 17 Safe-Enough Ideas

No stock is completely safe, but we can make educated guesses about which ones are likely to provide smooth sailing.

Kiplinger

What’s the link between talcum powder and cancer?

More than 1,300 Victorians have joined a class action against Johnson & Johnson alleging its talcum powder products left them with ovarian cancer, mesothelioma (cancer affecting the lungs) and other cancers affecting the reproductive organs.

The Conversation

Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector

Johnson & Johnson provides stability through decades of dividend growth while pivoting to high-margin medical technology to outperform the volatile market.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Is Johnson & Johnson Stock Outperforming the Nasdaq?

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Barchart

5 Dividend Stocks Retirees Are Favoring for Steady Income in 2026

Retirees in 2026 are looking for something simple: predictable income without unnecessary risk. With inflation still pressuring household budgets and bond yields bouncing around, many...

Saving Advice

Anger, distress but $405m mesh implant payouts coming

Exasperation over lengthy wait for women to be compensated for pelvic mesh implant injuries has led to promises that money will start flowing soon.

AAP

5 Stocks and ETFs to Help Shield Your Portfolio During Volatility

Resilient stocks and ETFs offering steady demand and dividend yields may help investors weather further market turbulence without abandoning equity exposure.

MarketBeat

Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs

Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is mixed. JNJ has many “Strong Buy” opinions, but some analysts consider JNJ overvalued. Today’s...

Barchart

What Are Wall Street Analysts' Target Price for Johnson & Johnson Stock?

Although Johnson & Johnson has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Barchart

1 Dividend King to Buy and Hold Through Any Market

In uncertain markets, reliable income matters more than ever. This Dividend King offers exactly that.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Johnson & Johnson Quietly Triggers a Trend Following Buy Signal

Johnson & Johnson is poised to advance in H2 2026 as growth, cash flow, and capital returns drive bullish analysts and institutional sentiment.

Barchart

Trump Speech, Earnings and Other Key Things to Watch this Week

Markets enter a holiday-shortened week with the Martin Luther King, Jr. Day closure Monday, followed by a convergence of events including President Trump's inauguration speech Wednesday at 8:30am

Woman & Home

'We don't want to fade away slowly' - Naomi Watts shares the important check many women miss in menopause

The star spoke exclusively to woman&home to share what she learnt about looking after her eyes in menopause

Barchart

2 Rock-Solid Dividend Stocks to Buy for Steady Passive Income

These two income stocks can weather every cycle.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

This ETF Is Proof That the Healthcare Rebound Is Real

Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.

MarketBeat

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

Barchart

2 Dividend Kings Quietly Beating the Market This Year

These two are the calm outperformers that might have been overlooked.

International Business Times

Johnson & Johnson Ordered to Pay $65.5 Million to a Woman in Talcum Powder Cancer Case

A Minnesota jury ordered Johnson & Johnson to pay $65.5 million to a mother of three who linked her cancer to long-term use of the company's talcum powder.

Barchart

What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report

Investor interest is building ahead of Johnson & Johnson’s Q4 earnings, backed by positive analyst sentiment.

The Independent UK

Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder

A Minnesota jury has awarded $65.5 million to a woman who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing mesothelioma

Barchart

3 Dividend Kings Delivering Generational Income & Market-Beating Returns

3 top-performing Dividend Kings of 2025 based on their Year-to-Date percent change.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.